NASDAQ:ABCL

AbCellera Biologics News Headlines

$25.90
+1.06 (+4.27 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$24.99
$26.49
50-Day Range
$23.84
$34.17
52-Week Range
$23.20
$71.91
Volume4.29 million shs
Average Volume1.12 million shs
Market Capitalization$7.02 billion
P/E Ratio57.56
Dividend YieldN/A
BetaN/A

AbCellera Biologics (NASDAQ ABCL) News Headlines Today

SourceHeadline
AbCellera Biologics (NASDAQ:ABCL) Trading 3.9% Higher AbCellera Biologics (NASDAQ:ABCL) Trading 3.9% Higher
americanbankingnews.com - June 11 at 10:46 AM
AbCellera Announces Secondary Private Sale of 11.9 Million Common SharesAbCellera Announces Secondary Private Sale of 11.9 Million Common Shares
finance.yahoo.com - June 10 at 7:46 PM
Andrew Booth Sells 1,200,000 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) StockAndrew Booth Sells 1,200,000 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) Stock
americanbankingnews.com - June 10 at 5:34 PM
AbCellera Biologics Inc. (NASDAQ:ABCL) Major Shareholder Holdings Ltd. Thermopylae Sells 5,598,420 SharesAbCellera Biologics Inc. (NASDAQ:ABCL) Major Shareholder Holdings Ltd. Thermopylae Sells 5,598,420 Shares
americanbankingnews.com - June 10 at 5:34 PM
AbCellera Biologics Inc. (NASDAQ:ABCL) CEO Sells $144,780,000.00 in StockAbCellera Biologics Inc. (NASDAQ:ABCL) CEO Sells $144,780,000.00 in Stock
americanbankingnews.com - June 10 at 5:34 PM
AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up to $23.84AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up to $23.84
americanbankingnews.com - June 10 at 11:35 AM
AbCellera Biologics (NASDAQ:ABCL) Sees Strong Trading VolumeAbCellera Biologics (NASDAQ:ABCL) Sees Strong Trading Volume
americanbankingnews.com - June 9 at 10:50 AM
AbCellera Biologics (NASDAQ:ABCL)  Shares Down 6.4% AbCellera Biologics (NASDAQ:ABCL) Shares Down 6.4%
americanbankingnews.com - June 3 at 3:35 PM
AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 7.7%AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 7.7%
americanbankingnews.com - May 26 at 12:29 PM
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Recommendation of "Buy" from BrokeragesAbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Recommendation of "Buy" from Brokerages
americanbankingnews.com - May 22 at 10:24 AM
AbCellera Biologics Breaks Below 200-Day Moving Average - Notable for ABCLAbCellera Biologics Breaks Below 200-Day Moving Average - Notable for ABCL
nasdaq.com - May 19 at 4:20 PM
These Analysts Just Made A Huge Downgrade To Their AbCellera Biologics Inc. (NASDAQ:ABCL) EPS ForecastsThese Analysts Just Made A Huge Downgrade To Their AbCellera Biologics Inc. (NASDAQ:ABCL) EPS Forecasts
nasdaq.com - May 16 at 7:43 PM
AbCellera Biologics Inc. (ABCL) CEO Carl Hansen on Q1 2021 Results - Earnings Call TranscriptAbCellera Biologics Inc. (ABCL) CEO Carl Hansen on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 12:42 AM
AbCellera to Present Virtually at Berenberg Conference on May 18, 2021AbCellera to Present Virtually at Berenberg Conference on May 18, 2021
finance.yahoo.com - May 11 at 4:16 PM
AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic RetinopathyAbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy
finance.yahoo.com - May 6 at 6:04 PM
New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical TrialsNew AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials
finance.yahoo.com - May 4 at 10:55 AM
AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech ProfessionalsAbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals
finance.yahoo.com - April 29 at 6:01 PM
AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021
finance.yahoo.com - April 21 at 5:00 PM
Is ABCL Stock A Buy or Sell?Is ABCL Stock A Buy or Sell?
finance.yahoo.com - April 20 at 3:54 PM
AbCellera to Present Virtually at Upcoming Investor ConferencesAbCellera to Present Virtually at Upcoming Investor Conferences
finance.yahoo.com - April 12 at 7:12 PM
Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19
finance.yahoo.com - April 5 at 5:40 PM
These Analysts Just Made An Incredible Downgrade To Their AbCellera Biologics Inc. (NASDAQ:ABCL) EPS ForecastsThese Analysts Just Made An Incredible Downgrade To Their AbCellera Biologics Inc. (NASDAQ:ABCL) EPS Forecasts
nasdaq.com - April 2 at 9:21 AM
AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Just Cut Their EPS Forecasts SubstantiallyAbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Just Cut Their EPS Forecasts Substantially
finance.yahoo.com - April 1 at 1:32 PM
AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery CollaborationAbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration
finance.yahoo.com - April 1 at 1:32 PM
AbCellera Biologics (ABCL) CEO Carl Hansen on Q4 2020 Results - Earnings Call TranscriptAbCellera Biologics' (ABCL) CEO Carl Hansen on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 31 at 8:15 PM
AbCellera Biologics EPS misses by $0.14, beats on revenueAbCellera Biologics EPS misses by $0.14, beats on revenue
seekingalpha.com - March 31 at 3:14 PM
AbCellera Reports Full Year 2020 Business ResultsAbCellera Reports Full Year 2020 Business Results
finance.yahoo.com - March 29 at 8:15 PM
What Percentage Of AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Do Insiders Own?What Percentage Of AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Do Insiders Own?
finance.yahoo.com - March 13 at 9:26 AM
EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 PatientsEMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients
finance.yahoo.com - March 5 at 7:53 PM
AbCellera Biologics Enters Oversold Territory (ABCL)AbCellera Biologics Enters Oversold Territory (ABCL)
nasdaq.com - March 4 at 1:46 PM
AbCellera Appoints Ester Falconer, Ph.D., as Chief Technology OfficerAbCellera Appoints Ester Falconer, Ph.D., as Chief Technology Officer
finance.yahoo.com - February 11 at 8:12 PM
The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOsThe Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs
msn.com - February 10 at 8:16 AM
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19
finance.yahoo.com - February 9 at 10:15 PM
AbCellera Announces Date of Fourth Quarter 2020 Financial Results Conference CallAbCellera Announces Date of Fourth Quarter 2020 Financial Results Conference Call
finance.yahoo.com - February 3 at 6:00 PM
AbCellera Biologics Inc. (ABCL)AbCellera Biologics Inc. (ABCL)
uk.finance.yahoo.com - January 28 at 11:16 PM
AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19
finance.yahoo.com - January 27 at 9:11 AM
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%
finance.yahoo.com - January 26 at 8:39 AM
AbCellera Granted U.S. Patent Covering its Trianni Mouse® TechnologyAbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology
finance.yahoo.com - January 19 at 6:45 PM
AbCellera Biologics, Inc. (ABCL)AbCellera Biologics, Inc. (ABCL)
realmoney.thestreet.com - January 7 at 1:11 AM
2020 Canadian IPO mixed results - number (77) down, amount ($5.55B) up driven by PE-backed IPOs2020 Canadian IPO mixed results - number (77) down, amount ($5.55B) up driven by PE-backed IPOs
finance.yahoo.com - January 5 at 2:01 PM
Why Is It Moving? Analyzing The Downward Movement in AbCellera Biologicss Stock TodayWhy Is It Moving? Analyzing The Downward Movement in AbCellera Biologics's Stock Today
msn.com - December 29 at 1:20 PM
AbCellera Biologics Inc.AbCellera Biologics Inc.
barrons.com - December 28 at 12:21 AM
AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New MexicoAbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico
finance.yahoo.com - December 21 at 9:42 AM
AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesAbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - December 16 at 12:46 AM
This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.